Alluvi, previously BI 4744, offers a significant advance in obesity care. This dual stimulator targeting both GLP-1 and GIP sites demonstrates remarkable effectiveness in patient assessments, possibly surpassing https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/